The 13D Report
The 13D Report
Shareholder activism
⌘K
Signup free
activistletters

Lynx1 Capital Challenges Neuphoria Therapeutics (NEUP) Board Over Entrenchment, Strategic Review Flaws, and Value Destruction

Summary

Lynx1’s presentation argues that Neuphoria’s leadership mishandled the failed AFFIRM-1 Phase 3 trial, lacked transparency, and pursued heavy dilution that destroyed shareholder value. It claims the Board is unprepared, conflicted, and resistant to engagement during a strategic review, including ignoring Lynx1’s acquisition offer and using tactics that entrench incumbents. Lynx1 frames its two nominees as experienced, independent biotech and capital-allocation experts who can restore discipline, halt reckless ATM issuance, and run a credible strategic alternatives process aimed at maximizing shareholder value.

Company Name: Neuphoria Therapeutics Inc.
Symbol: NEUP
Filing Date: Nov-26-2025
Filer Name: Lynx1 Capital Management LP

Download Presentation
Lynx1-11-26-2025.pdf
7 MB
download-circle

Source: 

https://www.sec.gov/Archives/edgar/data/1191070/000119312525300651/d95937ddfan14a.htm

Member discussion

More like this

Galloway Capital Presses Chicago Rivet (CVR) on Market Mispricing, Calls for Enhanced Investor Outreach

Summary Galloway Capital Partners, which owns about 6.45% of Chicago Rivet & Machine Co., argues that the company is

Ampco Pittsburgh (AP) Draws Activist Support From Galloway Capital Partners as Letter Highlights Valuation Gap and M&A Options

Summary Galloway Capital Partners disclosed that it has built a 5.19% stake in Ampco Pittsburgh over the past 18

STAAR Surgical (STAA) Faces Intensifying Pushback as Broadwood Partners Opposes Sale and Presses for Independence

Summary Broadwood strongly opposed STAAR Surgical’s proposed sale to Alcon, arguing the deal materially undervalues the company and reflects

OraSure Technologies (OSUR) Faces Proxy Fight as Altai Capital Seeks Board Seats Over Governance and Strategic Failures

Summary Altai Capital disclosed a 5.2% stake in OraSure and sharply criticized the Board for clinging to a failed

Global Crossing Airlines (JET) Draws Activist Interest as Galloway Capital Pushes M&A or Going-Private Options

Summary Galloway Capital disclosed that it has increased its stake in Global Crossing Airlines to 6.24%, reiterated its view

Yunqi Capital Challenges STAAR Surgical (STAA) Board, Rejects Alcon Merger Over Timing, Process, and Valuation

Summary In a December 10, 2025 letter, Yunqi Capital reiterated its opposition to STAAR Surgical’s proposed sale to Alcon,